Net Worth Advisory Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.26M Sell
2,715
-149
-5% -$152K 0.82% 17
2026
Q1
$2.63M Buy
2,864
+544
+23% +$552K 0.55% 34
2025
Q4
$2.49M Buy
2,320
+178
+8% +$170K 0.5% 41
2025
Q3
$1.63M Sell
2,142
-576
-21% -$429K 0.47% 42
2025
Q2
$2.12M Buy
2,718
+1,760
+184% +$1.37M 0.47% 44
2025
Q1
$792K Buy
958
+63
+7% +$52.4K 0.25% 83
2024
Q4
$691K Sell
895
-24
-3% -$19.9K 0.21% 103
2024
Q3
$814K Buy
+919
New +$826K 0.24% 80

Other funds holding LLY

Net Worth Advisory Group's LLY Position: Q2 2026 in Review

Net Worth Advisory Group reduced its Eli Lilly (LLY) stake by 5.2% in Q2 2026, selling an estimated $152K and leaving 2,715 shares worth $3.26M. The position accounts for 0.82% of the portfolio, ranked #17.

Net Worth Advisory Group first reported a position in LLY in Q3 2024 and has held it in 8 quarters since. 961 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Net Worth Advisory Group held 2,715 shares of Eli Lilly worth $3.26M as of Q2 2026.
  • Net Worth Advisory Group sold 149 Eli Lilly shares in Q2 2026, an estimated $152K.
  • Eli Lilly made up 0.82% of Net Worth Advisory Group's portfolio in Q2 2026, its #17 holding.
  • Net Worth Advisory Group first reported a position in Eli Lilly in Q3 2024 and has held it in 8 quarters since.
  • 961 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Net Worth Advisory Group's 13F filing for Q2 2026, filed 14 Jul 2026.